(42) proved that the regulation of the PI3K/AKT/NRF2 pathway activates and upregulates ABCC5 to promote the resistance of sorafenib (a first-line molecular targeted drug for advanced HCC) acquired in human HCC cells. The gene discussed is AKT1; the disease is hepatocellular carcinoma.